載入...
Treatment options after sorafenib failure in patients with hepatocellular carcinoma
Second line therapy after failure of sorafenib continues to be under study. Prognosis of hepatocellular carcinoma is measured in months, with median overall survival reaching 10.7 months with sorafenib. Because of the modest net benefit sorafenib has contributed, and rising incidence of hepatocellul...
Na minha lista:
| 發表在: | Clin Mol Hepatol |
|---|---|
| Main Authors: | , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
The Korean Association for the Study of the Liver
2017
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5760005/ https://ncbi.nlm.nih.gov/pubmed/29151326 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3350/cmh.2017.0108 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|